@article{TLCR19032,
author = {Malinda Itchins and Stephen Clarke and Nick Pavlakis},
title = {Do EGFR tyrosine kinase inhibitors (TKIs) still have a role in EGFR wild-type pre-treated advanced non-small cell lung cancer (NSCLC)?—the shifting paradigm of therapeutics},
journal = {Translational Lung Cancer Research},
volume = {7},
number = {Suppl 1},
year = {2018},
keywords = {},
abstract = {EGFR mutations are well established as important oncogenic drivers that occur in 10–44% of primary lung adenocarcinomas occurring more frequently in women, Asians and non-smokers (1,2).},
issn = {2226-4477}, url = {https://tlcr.amegroups.org/article/view/19032}
}